You just read:

German Institute for Quality and Efficiency in Health Care (IQWiG) Confirms Additional Benefit for Kisplyx® (lenvatinib) in Combination with everolimus for the Treatment of Advanced Renal Cell Carcinoma

News provided by

Eisai

04 Jan, 2017, 23:01 GMT